TABLE 6.

Incidence of treatment-emergent AEs occurring in at least 3% of patients in either treatment group

AE or characteristic	No. (%) of patients
	Ceftobiprole group (n = 389)	Vancomycin group (n = 382)
Nausea	55 (14)	29 (8)
Vomiting	27 (7)	15 (4)
Dysgeusia	30 (8)	2 (1)
Diarrhea	21 (5)	15 (4)
Constipation	14 (4)	11 (3)
Headache	27 (7)	24 (6)
Dizziness	14 (4)	8 (2)
Rash	9 (2)	11 (3)
Pruritus	12 (3)	22 (6)
At least one AE	203 (52)	193 (51)
At least one serious AE	24 (6)	23 (6)
Discontinuation due to AE	17 (4)	22 (6)